BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33639865)

  • 1. The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.
    Zhang W; Ren X; Qi L; Zhang C; Tu C; Li Z
    BMC Cancer; 2021 Feb; 21(1):202. PubMed ID: 33639865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.
    Ma B; Li M; Zhang L; Huang M; Lei JB; Fu GH; Liu CX; Lai QW; Chen QQ; Wang YL
    Tumour Biol; 2016 Apr; 37(4):4445-55. PubMed ID: 26499949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered long non-coding RNAs predict worse outcome in osteosarcoma patients: evidence from a meta-analysis.
    Yang Y; Wang S; Li T
    Oncotarget; 2017 May; 8(21):35234-35243. PubMed ID: 28415638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma.
    Wang Y; Zhao Z; Zhang S; Li Z; Li D; Yang S; Zhang H; Zeng X; Liu J
    J Cell Biochem; 2018 Nov; 119(10):8481-8489. PubMed ID: 29987852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of taurine upregulated gene 1 as a predictor of poor outcome in osteosarcoma.
    Wang Q; Chen Q
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S405-S409. PubMed ID: 29970697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis.
    Liu M; Yang P; Mao G; Deng J; Peng G; Ning X; Yang H; Sun H
    Int J Surg; 2019 Dec; 72():206-213. PubMed ID: 31734255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does serum alkaline phosphatase level really indicate the prognosis in patients with osteosarcoma? A meta-analysis.
    Gu R; Sun Y
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S468-S472. PubMed ID: 29970708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.
    Zhang P; Xu K; Wang J; Zhang J; Quan H
    BMC Cancer; 2021 Dec; 21(1):1285. PubMed ID: 34852770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling of long noncoding RNAs associated with vasculogenic mimicry in osteosarcoma.
    Ren K; Ni Y; Li X; Wang C; Chang Q; Li Y; Gao Z; Wu S; Shi X; Song J; Yao N; Zhou J
    J Cell Biochem; 2019 Aug; 120(8):12473-12488. PubMed ID: 30825232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA HOTTIP is up-regulated and associated with poor prognosis in patients with osteosarcoma.
    Li F; Cao L; Hang D; Wang F; Wang Q
    Int J Clin Exp Pathol; 2015; 8(9):11414-20. PubMed ID: 26617868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.
    Zeng M; Zhou J; Wen L; Zhu Y; Luo Y; Wang W
    BMC Cancer; 2021 Mar; 21(1):210. PubMed ID: 33648449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
    Wang Z; Liu Z; Wu S
    Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between PTEN and clinical-pathological features of osteosarcoma.
    Zhou J; Xiao X; Wang W; Luo Y
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31270249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA expression and implication in osteosarcoma: a systematic review and meta-analysis.
    Wang Y; Huang Y; Xiang P; Tian W
    Onco Targets Ther; 2017; 10():5355-5361. PubMed ID: 29184421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.
    Li Z; Dou P; Liu T; He S
    Cell Physiol Biochem; 2017; 42(4):1407-1419. PubMed ID: 28715796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of long non-coding RNA XIST in osteosarcoma is associated with cell proliferation and poor prognosis.
    Li GL; Wu YX; Li YM; Li J
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(12):2829-2834. PubMed ID: 28682435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Noncoding RNA XIST Promotes Osteosarcoma Progression by Targeting Ras-Related Protein RAP2B via miR-320b.
    Lv GY; Miao J; Zhang XL
    Oncol Res; 2018 Jul; 26(6):837-846. PubMed ID: 28409547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel antisense long non-coding RNA SATB2-AS1 overexpresses in osteosarcoma and increases cell proliferation and growth.
    Liu SH; Zhu JW; Xu HH; Zhang GQ; Wang Y; Liu YM; Liang JB; Wang YX; Wu Y; Guo QF
    Mol Cell Biochem; 2017 Jun; 430(1-2):47-56. PubMed ID: 28190168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk assessment model for the prognosis of osteosarcoma utilizing differentially expressed lncRNAs.
    Sun K; Zhao J
    Mol Med Rep; 2019 Feb; 19(2):1128-1138. PubMed ID: 30569146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.